Market Overview

UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Share:
Related
Wells Fargo Reacts To Regulus News Of FDA Request For Info Regarding Clinical Hold
Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold

Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.

Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."

Regulus Therapeutics closed at $4.34 on Wednesday.

Latest Ratings for RGLS

DateFirmActionFromTo
Jun 2016BMO CapitalDowngradesOutperformMarket Perform
Jun 2016Chardan CapitalMaintainsBuy
Apr 2016Chardan CapitalInitiates Coverage onBuy

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (RGLS)

View Comments and Join the Discussion!